<DOC>
	<DOCNO>NCT02500485</DOCNO>
	<brief_summary>The purpose study investigate potential interaction multiple oral dos SHR3824 multiple oral dos SP2086 healthy adult volunteer .</brief_summary>
	<brief_title>The Drug-drug Interaction SHR3824 SP2086</brief_title>
	<detailed_description>This open-label ( volunteer know name treatment assign ) single-center study SHR3824 SP2086 healthy adult volunteer . SHR3824 ( Sodium-Glucose Cotransporter 2 inhibitor ) currently development low blood sugar level patient type 2 diabetes mellitus ( T2DM ) , SP2086 ( Dipeptidyl peptidase IV inhibitor ) also currently development low blood sugar level patient type 2 diabetes mellitus ( T2DM ) .SP2086 administer orally ( mouth ) 100mg Days 1 , 2 , 3 , 4 , 15 , 16 , 17 18 , SHR3824 administer orally ( mouth ) 20mg Days 11 , 12 , 13 , 14 , 15 , 16 , 17 18 . Both SHR3824 SP2086 tablets take 8 ounce ( 240 mL ) water .</detailed_description>
	<criteria>Healthy volunteer body mass index ( BMI , measure person 's weight relation height ) 19 24 kg/m2 . History diabetes History heart failure renal insufficiency , Urinary tract infection , vulvovaginal mycotic infection History current clinically significant medical illness determine Investigator History clinically significant allergy , especially know hypersensitivity intolerance lactose Known allergy SHR3824 SP2086 excipients formulation SHR3824 SP2086</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>SHR3824 SP2086 drug-drug interaction</keyword>
</DOC>